{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:56:37Z","timestamp":1787849797891,"version":"build-2784847793"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ecl.2017.04.004","type":"journal-article","created":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T00:01:30Z","timestamp":1497312090000},"page":"669-677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Biochemical Testing in Neuroendocrine Tumors"],"prefix":"10.1016","volume":"46","author":[{"given":"Vidya","family":"Aluri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.ecl.2017.04.004_bib1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2017.04.004_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","article-title":"The epidemiology of gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"10.1016\/j.ecl.2017.04.004_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000151562","article-title":"Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France","volume":"89","author":"Lombard-Bohas","year":"2009","journal-title":"Neuroendocrinology"},{"issue":"9130","key":"10.1016\/j.ecl.2017.04.004_bib4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0140-6736(98)02286-7","article-title":"Carcinoid tumour","volume":"352","author":"Caplin","year":"1998","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ecl.2017.04.004_bib5","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","article-title":"Current status of gastrointestinal carcinoids","volume":"128","author":"Modlin","year":"2005","journal-title":"Gastroenterology"},{"issue":"3 Suppl","key":"10.1016\/j.ecl.2017.04.004_bib6","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1007\/BF01536042","article-title":"Use of somatostatin analog in management of carcinoid syndrome","volume":"34","author":"Vinik","year":"1989","journal-title":"Dig Dis Sci"},{"issue":"8","key":"10.1016\/j.ecl.2017.04.004_bib7","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/MPA.0b013e3181bc0e77","article-title":"Biochemical testing for neuroendocrine tumors","volume":"38","author":"Vinik","year":"2009","journal-title":"Pancreas"},{"issue":"12","key":"10.1016\/j.ecl.2017.04.004_bib8","doi-asserted-by":"crossref","first-page":"e16010","DOI":"10.1371\/journal.pone.0016010","article-title":"Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors","volume":"5","author":"Cui","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ecl.2017.04.004_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-5926-3-8","article-title":"Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C","volume":"3","author":"Poynard","year":"2004","journal-title":"Comp Hepatol"},{"key":"10.1016\/j.ecl.2017.04.004_bib10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4137\/BIC.S9455","article-title":"Molecular profiling for breast cancer: a comprehensive review","volume":"5","author":"Kittaneh","year":"2013","journal-title":"Biomark Cancer"},{"issue":"4","key":"10.1016\/j.ecl.2017.04.004_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1530\/EC-14-0100","article-title":"A\u00a0PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors","volume":"3","author":"Modlin","year":"2014","journal-title":"Endocr Connect"},{"issue":"5","key":"10.1016\/j.ecl.2017.04.004_bib12","doi-asserted-by":"crossref","first-page":"e63364","DOI":"10.1371\/journal.pone.0063364","article-title":"The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood","volume":"8","author":"Modlin","year":"2013","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.ecl.2017.04.004_bib13","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1200\/JCO.2006.10.1535","article-title":"Chromogranin A: is it a useful marker of neuroendocrine tumors?","volume":"25","author":"Campana","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2017.04.004_bib14","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/ki.1990.71","article-title":"Chromogranin A in uremia: progressive retention of immunoreactive fragments","volume":"37","author":"Hsiao","year":"1990","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.ecl.2017.04.004_bib15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ecl.2010.12.001","article-title":"The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"10.1016\/j.ecl.2017.04.004_bib16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3109\/1354750X.2012.654511","article-title":"Limitations of chromogranin A in clinical practice","volume":"17","author":"Marotta","year":"2012","journal-title":"Biomarkers"},{"issue":"9","key":"10.1016\/j.ecl.2017.04.004_bib17","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1245\/s10434-010-1006-3","article-title":"Chromogranin A\u2013biological function and clinical utility in neuro endocrine tumor disease","volume":"17","author":"Modlin","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ecl.2017.04.004_bib18","first-page":"1109","article-title":"The utility of circulating levels of human pancreatic polypeptide as a marker for islet cell tumors","volume":"108","author":"Langstein","year":"1990","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.ecl.2017.04.004_bib19","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1053\/j.gastro.2008.05.047","article-title":"Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors","volume":"135","author":"Metz","year":"2008","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ecl.2017.04.004_bib20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0002-9610(03)00115-6","article-title":"Serum peptide profiles in patients with carcinoid tumors","volume":"186","author":"Calhoun","year":"2003","journal-title":"Am J Surg"},{"issue":"4","key":"10.1016\/j.ecl.2017.04.004_bib21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MPA.0b013e318249a92a","article-title":"Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?","volume":"41","author":"Ito","year":"2012","journal-title":"Pancreas"},{"issue":"4","key":"10.1016\/j.ecl.2017.04.004_bib22","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MPA.0b013e318243a0b6","article-title":"A\u00a0prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans","volume":"41","author":"Raines","year":"2012","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.ecl.2017.04.004_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1677\/joe.0.1440049","article-title":"Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours","volume":"144","author":"Stridsberg","year":"1995","journal-title":"J\u00a0Endocrinol"},{"issue":"11","key":"10.1016\/j.ecl.2017.04.004_bib24","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1136\/gut.2006.092320","article-title":"Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours","volume":"55","author":"Turner","year":"2006","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.ecl.2017.04.004_bib25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/MPA.0b013e318271c0d5","article-title":"A\u00a0single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs)","volume":"42","author":"Tellez","year":"2013","journal-title":"Pancreas"},{"issue":"6","key":"10.1016\/j.ecl.2017.04.004_bib26","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/MPA.0b013e3181ebaffd","article-title":"NANETS consensus guidelines for the diagnosis of neuroendocrine tumor","volume":"39","author":"Vinik","year":"2010","journal-title":"Pancreas"},{"issue":"Pt 6","key":"10.1016\/j.ecl.2017.04.004_bib27","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/000456320203900605","article-title":"Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease","volume":"39","author":"Carling","year":"2002","journal-title":"Ann Clin Biochem"},{"issue":"1","key":"10.1016\/j.ecl.2017.04.004_bib28","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1006\/bbrc.1993.2243","article-title":"On the accurate determination of serotonin in human plasma","volume":"196","author":"Beck","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"10.1016\/j.ecl.2017.04.004_bib29","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/clinchem\/46.10.1588","article-title":"Discriminating capacity of indole markers in the diagnosis of carcinoid tumors","volume":"46","author":"Meijer","year":"2000","journal-title":"Clin Chem"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852917300348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852917300348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:42:46Z","timestamp":1760175766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852917300348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0889852917300348"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2017.04.004","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biochemical Testing in Neuroendocrine Tumors","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2017.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}